自体调节性T细胞过继输注治疗难治性溃疡性结肠炎合并原发性硬化性胆管炎
本文报告一例难治性溃疡性结肠炎合并原发性硬化性胆管炎患者,接受单次1×10^6/kg体重自体体外扩增多克隆调节性T细胞输注,在第4周和第12周评估临床、生化、内镜和组织学应答,结果观察到至第12周出现应答,并伴肠道CD3+/FoxP3+和CD3+/IL-10+ T细胞富集及黏膜转化生长因子β和双调蛋白水平升高,肝酶下降持续4周后回升。
要点
- 单次输注1×10^6/kg自体体外扩增多克隆调节性T细胞后,患者至第12周出现临床、生化、内镜和组织学应答。
- 输注与肠道CD3+/FoxP3+和CD3+/IL-10+ T细胞富集及黏膜转化生长因子β和双调蛋白水平升高相关。
- 原发性硬化性胆管炎肝酶明显改善,该效应持续4周后数值开始回升。
核心结论
- 这些发现提示过继性调节性T细胞治疗可能对难治性溃疡性结肠炎有效,并可能为原发性硬化性胆管炎的临床试验开辟新途径。
研究设计与样本
- 本文报告一例难治性溃疡性结肠炎合并原发性硬化性胆管炎患者接受单次1×10^6/kg体重自体体外扩增多克隆调节性T细胞输注,并在输注后第4周和第12周评估临床、生化、内镜和组织学应答。
主要发现
- 患者至输注后第12周出现临床、生化、内镜和组织学应答。
- 输注与肠道CD3+/FoxP3+和CD3+/IL-10+ T细胞富集及黏膜转化生长因子β和双调蛋白水平升高相关。
- 原发性硬化性胆管炎明显改善,肝酶下降,该效应持续4周后数值开始回升。
关键数值与推荐
- 单次输注剂量为1×10^6/kg体重的自体体外扩增多克隆调节性T细胞。
- 评估时间点为过继性调节性T细胞输注后第4周和第12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ulcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with refractory UC and associated primary sclerosing cholangitis (PSC), for which effective therapy is currently not available. DESIGN: The patient received a single infusion of 1×106 autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and histological responses were assessed 4 and 12 weeks after adoptive Treg transfer. RESULTS: The patient showed clinical, biochemical, endoscopic and histological signs of response until week 12 after adoptive Treg transfer, which was associated with an enrichment of intestinal CD3+/FoxP3+ and CD3+/IL-10+ T cells and increased mucosal transforming growth factor beta and amphiregulin levels. Moreover, there was marked improvement of PSC with reduction of liver enzymes. This pronounced effect lasted for 4 weeks before values started to increase again. CONCLUSION: These findings suggest that adoptive Treg therapy might be effective in refractory UC and might open new avenues for clinical trials in PSC. TRIAL REGISTRATION NUMBER: NCT04691232.
引用
- Voskens C, Stoica D, Rosenberg M, et al. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut. 2022. PMID: 35428657. doi:10.1136/gutjnl-2022-327075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。